CONCI, NICOLE
CONCI, NICOLE
Borsisti
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
2023 Conci, Nicole; Tassinari, Elisa; Tateo, Valentina; Rosellini, Matteo; Marchetti, Andrea; Ricci, Costantino; Chessa, Francesco; Santoni, Matteo; Grande, Enrique; Mollica, Veronica; Massari, Francesco
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report
2023 Elisa Tassinari, Nicole Conci, Giacomo Battisti, Francesco Porta, Valerio Di Scioscio, Maria Giulia Pirini, Dario de Biase, Maria Concetta Nigro, Miriam Iezza, Fausto Castagnetti, Luigi Lovato, Stefano Fanti, Maria Abbondanza Pantaleo, Margherita Nannini
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC
2022 Dall'Olio, Filippo G; Parisi, Claudia; Marcolin, Laura; Brocchi, Stefano; Caramella, Caroline; Conci, Nicole; Carpani, Giulia; Gelsomino, Francesco; Ardizzoni, Stefano; Marchese, Paola Valeria; Paccapelo, Alexandro; Grilli, Giada; Golfieri, Rita; Besse, Benjamin; Ardizzoni, Andrea
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
2021 Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S, Ambrosini V, Ardizzoni A.
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis
2021 Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A.
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
2021 Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter
2020 Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? | Conci, Nicole; Tassinari, Elisa; Tateo, Valentina; Rosellini, Matteo; Marchetti, Andrea; Ricci, C...ostantino; Chessa, Francesco; Santoni, Matteo; Grande, Enrique; Mollica, Veronica; Massari, Francesco | 2023-01-01 | MOLECULAR DIAGNOSIS & THERAPY | - | 1.01 Articolo in rivista | Molecular Diagn Ther 2023 [Neoadj UC].pdf |
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report | Elisa Tassinari, Nicole Conci, Giacomo Battisti, Francesco Porta, Valerio Di Scioscio, Maria Giul...ia Pirini, Dario de Biase, Maria Concetta Nigro, Miriam Iezza, Fausto Castagnetti, Luigi Lovato, Stefano Fanti, Maria Abbondanza Pantaleo, Margherita Nannini | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | Tassinari, Conci Front Oncol 2023.pdf |
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC | Dall'Olio, Filippo G; Parisi, Claudia; Marcolin, Laura; Brocchi, Stefano; Caramella, Caroline; Co...nci, Nicole; Carpani, Giulia; Gelsomino, Francesco; Ardizzoni, Stefano; Marchese, Paola Valeria; Paccapelo, Alexandro; Grilli, Giada; Golfieri, Rita; Besse, Benjamin; Ardizzoni, Andrea | 2022-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 12. Dall'Olio_Monitoring Tumor Growth Rate to predict Immune Checkpoint Inhibitors’ treatment outcome in advanced NSCLC.pdf |
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. | Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S..., Ambrosini V, Ardizzoni A. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis | Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors | Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontan...a F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A. | 2021-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience | Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppion...i E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A. | 2020-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter | Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A. | 2020-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |